全文获取类型
收费全文 | 13360篇 |
免费 | 696篇 |
国内免费 | 70篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 303篇 |
妇产科学 | 135篇 |
基础医学 | 1531篇 |
口腔科学 | 271篇 |
临床医学 | 889篇 |
内科学 | 3955篇 |
皮肤病学 | 163篇 |
神经病学 | 951篇 |
特种医学 | 489篇 |
外科学 | 2520篇 |
综合类 | 25篇 |
预防医学 | 303篇 |
眼科学 | 175篇 |
药学 | 973篇 |
中国医学 | 26篇 |
肿瘤学 | 1326篇 |
出版年
2023年 | 83篇 |
2022年 | 48篇 |
2021年 | 241篇 |
2020年 | 167篇 |
2019年 | 207篇 |
2018年 | 284篇 |
2017年 | 222篇 |
2016年 | 272篇 |
2015年 | 310篇 |
2014年 | 347篇 |
2013年 | 473篇 |
2012年 | 713篇 |
2011年 | 867篇 |
2010年 | 489篇 |
2009年 | 410篇 |
2008年 | 735篇 |
2007年 | 829篇 |
2006年 | 760篇 |
2005年 | 781篇 |
2004年 | 808篇 |
2003年 | 771篇 |
2002年 | 711篇 |
2001年 | 334篇 |
2000年 | 344篇 |
1999年 | 274篇 |
1998年 | 143篇 |
1997年 | 134篇 |
1996年 | 91篇 |
1995年 | 101篇 |
1994年 | 91篇 |
1993年 | 101篇 |
1992年 | 185篇 |
1991年 | 185篇 |
1990年 | 178篇 |
1989年 | 184篇 |
1988年 | 141篇 |
1987年 | 145篇 |
1986年 | 151篇 |
1985年 | 140篇 |
1984年 | 76篇 |
1983年 | 76篇 |
1982年 | 47篇 |
1980年 | 33篇 |
1979年 | 40篇 |
1978年 | 38篇 |
1977年 | 29篇 |
1975年 | 30篇 |
1971年 | 35篇 |
1970年 | 32篇 |
1968年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Chronic infection with Helicobacter pylori cagA‐positive strains is causally associated with the development of gastric diseases, most notably gastric cancer. The cagA‐encoded CagA protein, which is injected into gastric epithelial cells by bacterial type IV secretion, undergoes tyrosine phosphorylation at the Glu‐Pro‐Ile‐Tyr‐Ala (EPIYA) segments (EPIYA‐A, EPIYA‐B, EPIYA‐C, and EPIYA‐D), which are present in various numbers and combinations in its C‐terminal polymorphic region, thereby enabling CagA to promiscuously interact with SH2 domain‐containing host cell proteins, including the prooncogenic SH2 domain‐containing protein tyrosine phosphatase 2 (SHP2). Perturbation of host protein functions by aberrant complex formation with CagA has been considered to contribute to the development of gastric cancer. Here we show that SHIP2, an SH2 domain‐containing phosphatidylinositol 5′‐phosphatase, is a hitherto undiscovered CagA‐binding host protein. Similar to SHP2, SHIP2 binds to the Western CagA‐specific EPIYA‐C segment or East Asian CagA‐specific EPIYA‐D segment through the SH2 domain in a tyrosine phosphorylation‐dependent manner. In contrast to the case of SHP2, however, SHIP2 binds more strongly to EPIYA‐C than to EPIYA‐D. Interaction with CagA tethers SHIP2 to the plasma membrane, where it mediates production of phosphatidylinositol 3,4‐diphosphate [PI(3,4)P2]. The CagA‐SHIP2 interaction also potentiates the morphogenetic activity of CagA, which is caused by CagA‐deregulated SHP2. This study indicates that initially delivered CagA interacts with SHIP2 and thereby strengthens H. pylori‐host cell attachment by altering membrane phosphatidylinositol compositions, which potentiates subsequent delivery of CagA that binds to and thereby deregulates the prooncogenic phosphatase SHP2. 相似文献
3.
4.
5.
6.
7.
Mai Ishikawa Yukie Endo Akihito Uehara Mariko Suto Masahito Yasuda Sei‐ichiro Motegi Osamu Ishikawa 《The Journal of dermatology》2019,46(2):161-165
Histiocytoses, including Langerhans cell histiocytosis (LCH), juvenile or adult xanthogranuloma (AXG) and Rosai–Dorfman disease (RDD), are rare disorders characterized by the proliferation of cells derived from monocyte/macrophage lineages. A few cases of LCH coexisting with xanthogranuloma or RDD have been reported. The etiology of these diseases remains unclear. However, oncogenic BRAFV600E mutations have been identified in LCH. Here, we report the case of a 26‐year‐old Japanese man with a 3‐month history of a solitary occipital nodule. No abnormality was detected in his other organs, and a total resection of the nodule was performed. Histopathological examination revealed the coexistence of LCH and AXG with prominent emperipolesis characteristic of RDD. Immunohistochemistry showed that most of the large histiocytes were positive for CD68, weakly positive or negative for S100, and negative for CD207 and CD1a, supporting the diagnosis of AXG. The tumor cells with emperipolesis did not show S100‐positive findings characteristic of RDD. The focally aggregated oval histiocytic cells were positive for CD1a, CD207, CD68 and S100, and were compatible with the immunophenotype of LCH cells. In addition, these cells were positive for BRAFV600E mutation. The tumor cells in our patient exhibited a cellular morphology characteristic of multiple histiocytoses in a solitary cutaneous nodule, which may imply an etiological association among LCH, AXG and RDD. To our knowledge, this is the first report of a BRAFV600E mutation‐positive case of LCH coexisting with AXG. Because patients with BRAFV600E mutation have higher risks of multisystemic LCH and recurrence, we should carefully follow up the patient. 相似文献
8.
Takeshi Nagashima Ken Yamaguchi Kenichi Urakami Yuji Shimoda Sumiko Ohnami Keiichi Ohshima Tomoe Tanabe Akane Naruoka Fukumi Kamada Masakuni Serizawa Keiichi Hatakeyama Kenya Matsumura Shumpei Ohnami Koji Maruyama Tohru Mochizuki Masatoshi Kusuhara Akio Shiomi Yasuhisa Ohde Masanori Terashima Katsuhiko Uesaka Tetsuro Onitsuka Seiichiro Nishimura Yasuyuki Hirashima Nakamasa Hayashi Yoshio Kiyohara Yasuhiro Tsubosa Hirohisa Katagiri Masashi Niwakawa Kaoru Takahashi Hiroya Kashiwagi Masahiro Nakagawa Yuji Ishida Takashi Sugino Mitsuru Takahashi Yasuto Akiyama 《Cancer science》2020,111(2):687-699
This study aimed to establish the Japanese Cancer Genome Atlas (JCGA) using data from fresh frozen tumor tissues obtained from 5143 Japanese cancer patients, including those with colorectal cancer (31.6%), lung cancer (16.5%), gastric cancer (10.8%) and other cancers (41.1%). The results are part of a single‐center study called “High‐tech Omics‐based Patient Evaluation” or “Project HOPE” conducted at the Shizuoka Cancer Center, Japan. All DNA samples and most RNA samples were analyzed using whole‐exome sequencing, cancer gene panel sequencing, fusion gene panel sequencing and microarray gene expression profiling, and the results were annotated using an analysis pipeline termed “Shizuoka Multi‐omics Analysis Protocol” developed in‐house. Somatic driver alterations were identified in 72.2% of samples in 362 genes (average, 2.3 driver events per sample). Actionable information on drugs that is applicable in the current clinical setting was associated with 11.3% of samples. When including those drugs that are used for investigative purposes, actionable information was assigned to 55.0% of samples. Germline analysis revealed pathogenic mutations in hereditary cancer genes in 9.2% of samples, among which 12.2% were confirmed as pathogenic mutations by confirmatory test. Pathogenic mutations associated with non–cancerous hereditary diseases were detected in 0.4% of samples. Tumor mutation burden (TMB) analysis revealed 5.4% of samples as having the hypermutator phenotype (TMB ≥ 20). Clonal hematopoiesis was observed in 8.4% of samples. Thus, the JCGA dataset and the analytical procedures constitute a fundamental resource for genomic medicine for Japanese cancer patients. 相似文献
9.